Brief: Humanigen Announces Oral Presentation Of Lenzilumab Phase 3 Study Results At Idweek 2021

Humanigen

29/09/2021 13:38

Sept 29 (Reuters) - Humanigen Inc  HGEN.O :
    * HUMANIGEN ANNOUNCES ORAL PRESENTATION OF LENZILUMAB
LIVE-AIR
PHASE 3 STUDY RESULTS AT IDWEEK 2021
    * HUMANIGEN INC - LENZILUMAB SIGNIFICANTLY IMPROVED
LIKELIHOOD OF
SURVIVAL WITHOUT VENTILATION (SWOV) BY 54%
    * HUMANIGEN INC - LIVE-AIR STUDY ACHIEVED ITS PRIMARY
ENDPOINT
    * HUMANIGEN INC - IN THIS STUDY, LENZILUMAB APPEARED TO BE
SAFE
AND WELL-TOLERATED, THERE WERE NO SERIOUS ADVERSE EVENTS (SAES)
ATTRIBUTED TO LENZILUMAB

Source text for Eikon:  ID:nBw63WqbHa 
Further company coverage:  HGEN.O 

 ((Reuters.Briefs@thomsonreuters.com;))